Cotinga Pharmaceuticals Inc. (COTQF)

[rbd317]

COTI-2 represents a potential breakthrough treatment

Our lead drug candidate, a small molecule called COTI-2, acts by normalizing the p53 protein function in cancer cells with mutation in the p53 gene. P53 mutations are common in gynecologic cancers with more than 95% of advanced ovarian cancers having this mutation. It appears that of all the ovarian cancer drugs in development at this time, COTI-2 offers the most exciting treatment opportunity. In fact, we believe that COTI-2 may represent a significant potential therapeutic advantage over treatments currently available for ovarian and other gynecologic cancers.

#COTQF / #COT.V